1 – 5 of 21
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies
(
- Contribution to journal › Article
- 2023
-
Mark
Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
(
- Contribution to journal › Article
- 2022
-
Mark
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity
(
- Contribution to journal › Article
- 2017
-
Mark
MIF inhibition interferes with the inflammatory and T cell-stimulatory capacity of NOD macrophages and delays autoimmune diabetes onset
(
- Contribution to journal › Article
- 2016
-
Mark
Initiation of T cell signaling by CD45 segregation at 'close contacts'
(
- Contribution to journal › Article